ABX464 for Crohn’s Disease

ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory efficacy in a completed Phase 2a induction study as well as a 24-month maintenance study in patients with moderate-to-severe ulcerative colitis (UC).

Due the clinical similarities of Crohn’s disease (CD) and UC, and the predictability of the DSS model for both UC and CD, several key opinion leaders (KOLs) are confident that ABX464 will also show beneficial effects in patients suffering from CD.

Based on the good safety profile and promising efficacy results obtained for ABX464 in UC, Abivax has been encouraged by KOLs to initiate a pivotal Phase 2b/3 trial for the treatment of CD. Abivax is currently planning for a start of the enrollment of patients in the beginning of 2021.